The Food and Drug Administration approves CAR T-Cell therapy Carvykti® as a second-line treatment and the CAR T-Cell therapy Abecma® as a third-line treatment for adult patients with multiple myeloma.

A growing trend in non-profit cancer research, board members who dedicate philanthropy in honor of a loved one who died from the disease. While multiple myeloma survival rates have increased, the need for continued research is a commitment for some.

The contemporary furniture that has graced the set of NBC 17's morning show "My Carolina Today" for the past three months is about to be sold to the highest bidder. Nowell's Contemporary Furniture in Cary is holding an auction of the furnitur

There are 173 drugs in clinical development for these indications, the majority of which are molecular targeted therapies (MTTs). This contrasts with HL and MDS where there is limited pipeline activity.

For more than five decades, ASH has sponsored its annual meeting, the premier annual education and scientific event in the field of hematology, and has published Blood, the Journal of the American Society of Hematology, which is the most cited peer-r